Dexamethasone and Dexmedetomidine for Preventing Nausea and Vomiting After Cesarean Section

Investigating the preventive effect of different doses of intravenous and intrathecal dexamethasone and dexmedetomidine on nausea and vomiting after cesarean section

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240221061070N10

Enrollment

270

Registered

2026-01-01

Start date

2025-12-28

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting after cesarean section. Nausea and vomiting

Interventions

Intervention 1: Intervention group: Intravenous dexamethasone 2 mg. The drug is diluted in 2 ml of normal saline and administered as a slow intravenous injection 10 minutes before the start of the ces

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18 to 45 years American Society of Anesthesiologists (ASA) physical status II Candidates for elective cesarean section under spinal anesthesia Provision of informed consent

Exclusion criteria

Exclusion criteria: Significant cardiac, pulmonary, hepatic, or renal disease Diabetes mellitus or thyroid disorders History of psychiatric disorders or substance abuse Use of vasodilator drugs or labor analgesics Baseline body temperature 37.5°C Requirement for blood transfusion during surgery

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative nausea and vomiting after cesarean section. Timepoint: Within the first 24 hours after the end of the surgical procedure. Method of measurement: Documentation of the presence or absence of any episode of nausea or vomiting by a blinded assessor.;Severity of nausea and vomiting. Timepoint: Within the first 24 hours after the end of the surgical procedure. Method of measurement: Assessment using a 4-point numerical scale (0: no symptoms, 1: mild nausea, 2: severe nausea, 3: vomiting, 4: severe vomiting).;Patient satisfaction level. Timepoint: 24 hours after the surgical procedure. Method of measurement: Direct questioning of the patient and recording responses based on a 5-point Likert scale (1: completely dissatisfied, 5: completely satisfied).	—

Measure

Time frame

Incidence of postoperative nausea and vomiting after cesarean section. Timepoint: Within the first 24 hours after the end of the surgical procedure. Method of measurement: Documentation of the presence or absence of any episode of nausea or vomiting by a blinded assessor.;Severity of nausea and vomiting. Timepoint: Within the first 24 hours after the end of the surgical procedure. Method of measurement: Assessment using a 4-point numerical scale (0: no symptoms, 1: mild nausea, 2: severe nausea, 3: vomiting, 4: severe vomiting).;Patient satisfaction level. Timepoint: 24 hours after the surgical procedure. Method of measurement: Direct questioning of the patient and recording responses based on a 5-point Likert scale (1: completely dissatisfied, 5: completely satisfied).

—

Secondary

Measure	Time frame
Changes in mean arterial pressure. Timepoint: Immediately before administration of the study drugs (baseline) and at 5, 15, 30, and 60 minutes after administration. Method of measurement: Non-invasive measurement using a standard operating room blood pressure monitor.;Changes in heart rate. Timepoint: Immediately before administration of the study drugs (baseline) and at 5, 15, 30, and 60 minutes after administration. Method of measurement: Continuous monitoring using a vital signs monitor and recording values at specified time points.;Incidence of drug-related adverse effects. Timepoint: During the surgical procedure and up to 24 hours postoperatively. Method of measurement: Documentation of the presence or absence of specified adverse effects (hypotension, bradycardia, dry mouth, sedation) by a blinded assessor.	—

Measure

Time frame

Changes in mean arterial pressure. Timepoint: Immediately before administration of the study drugs (baseline) and at 5, 15, 30, and 60 minutes after administration. Method of measurement: Non-invasive measurement using a standard operating room blood pressure monitor.;Changes in heart rate. Timepoint: Immediately before administration of the study drugs (baseline) and at 5, 15, 30, and 60 minutes after administration. Method of measurement: Continuous monitoring using a vital signs monitor and recording values at specified time points.;Incidence of drug-related adverse effects. Timepoint: During the surgical procedure and up to 24 hours postoperatively. Method of measurement: Documentation of the presence or absence of specified adverse effects (hypotension, bradycardia, dry mouth, sedation) by a blinded assessor.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMilad Masaeli

Esfahan University of Medical Sciences

drmilmas@gmail.com+98 31 3236 7001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026